Stockman Wealth Management’s BlackRock Health Sciences Trust II BMEZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-10,300
Closed -$158K 183
2024
Q2
$158K Hold
10,300
0.03% 173
2024
Q1
$169K Hold
10,300
0.03% 175
2023
Q4
$151K Hold
10,300
0.03% 171
2023
Q3
$148K Sell
10,300
-900
-8% -$14K 0.03% 182
2023
Q2
$184K Sell
11,200
-5,050
-31% -$82.3K 0.04% 183
2023
Q1
$272K Sell
16,250
-525
-3% -$8.46K 0.06% 167
2022
Q4
$259K Hold
16,775
0.06% 169
2022
Q3
$250K Hold
16,775
0.07% 158
2022
Q2
$276K Sell
16,775
-2,600
-13% -$44.6K 0.07% 148
2022
Q1
$389K Sell
19,375
-330
-2% -$6.85K 0.08% 134
2021
Q4
$500K Sell
19,705
-2,450
-11% -$63.2K 0.1% 119
2021
Q3
$598K Sell
22,155
-400
-2% -$11.5K 0.13% 100
2021
Q2
$652K Buy
22,555
+2,259
+11% +$62.5K 0.16% 91
2021
Q1
$534K Buy
20,296
+12,696
+167% +$360K 0.15% 102
2020
Q4
$218K Buy
+7,600
New +$202K 0.07% 166

Other funds holding BMEZ

Stockman Wealth Management's BMEZ Position: Q3 2024 in Review

Stockman Wealth Management sold out of BlackRock Health Sciences Trust II (BMEZ) in Q3 2024, closing a stake of 10,300 shares — an estimated $158K sold.

Stockman Wealth Management first reported a position in BMEZ in Q4 2020 and held it in 15 quarters. The position peaked at $652K in Q2 2021. 92 funds tracked by Wall St. Rank hold BMEZ as of Q3 2024.

  • Stockman Wealth Management reported no remaining BlackRock Health Sciences Trust II position as of Q3 2024 after selling out during the quarter.
  • Stockman Wealth Management sold 10,300 BlackRock Health Sciences Trust II shares in Q3 2024, an estimated $158K.
  • Stockman Wealth Management first reported a position in BlackRock Health Sciences Trust II in Q4 2020 and held it in 15 quarters.
  • Stockman Wealth Management's BlackRock Health Sciences Trust II position peaked at $652K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust II as of Q3 2024.

Based on Stockman Wealth Management's 13F filing for Q3 2024, filed 4 Nov 2024.